JP2019521156A - Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 - Google Patents

Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 Download PDF

Info

Publication number
JP2019521156A
JP2019521156A JP2019502063A JP2019502063A JP2019521156A JP 2019521156 A JP2019521156 A JP 2019521156A JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019521156 A JP2019521156 A JP 2019521156A
Authority
JP
Japan
Prior art keywords
seq
antibody
patient
binding fragment
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521156A5 (enrdf_load_stackoverflow
Inventor
ファッシュ，アンドレアス
オリバー，ジェイミー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59677269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019521156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019521156A publication Critical patent/JP2019521156A/ja
Publication of JP2019521156A5 publication Critical patent/JP2019521156A5/ja
Priority to JP2022100449A priority Critical patent/JP2022126791A/ja
Priority to JP2023172063A priority patent/JP2024001125A/ja
Priority to JP2025058479A priority patent/JP2025102888A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019502063A 2016-07-19 2017-07-18 Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 Pending JP2019521156A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022100449A JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364007P 2016-07-19 2016-07-19
US62/364,007 2016-07-19
PCT/IB2017/054333 WO2018015880A1 (en) 2016-07-19 2017-07-18 Methods of treating new-onset plaque type psoriasis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100449A Division JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Publications (2)

Publication Number Publication Date
JP2019521156A true JP2019521156A (ja) 2019-07-25
JP2019521156A5 JP2019521156A5 (enrdf_load_stackoverflow) 2020-08-27

Family

ID=59677269

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019502063A Pending JP2019521156A (ja) 2016-07-19 2017-07-18 Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2022100449A Withdrawn JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A Pending JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A Pending JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022100449A Withdrawn JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A Pending JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A Pending JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Country Status (6)

Country Link
US (2) US20190194311A1 (enrdf_load_stackoverflow)
EP (2) EP3487881B1 (enrdf_load_stackoverflow)
JP (4) JP2019521156A (enrdf_load_stackoverflow)
CN (1) CN109476733A (enrdf_load_stackoverflow)
ES (1) ES2992409T3 (enrdf_load_stackoverflow)
WO (1) WO2018015880A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023064023A (ja) * 2021-10-25 2023-05-10 良丹 孫 乾癬を治療／抑制するための医薬の製造における試薬の使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476733A (zh) 2016-07-19 2019-03-15 诺华股份有限公司 使用il-17拮抗剂治疗新发斑块型银屑病的方法
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN114127108A (zh) * 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
EP3797779A1 (en) * 2019-09-30 2021-03-31 Servei de Salut de Les Illes Balears - Ibsalut Combined therapy comprising an inhibitor of interleukin-17 activity and a vitamin d receptor agonist
AU2020396455A1 (en) * 2019-12-06 2022-06-02 Novartis Ag Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103153A1 (en) * 2014-12-22 2016-06-30 Novartis Ag Pharmaceutical products and stable liquid compositions of il-17 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP3808769A1 (en) 2005-12-13 2021-04-21 Eli Lilly And Company Anti-il-17 antibodies
RU2430110C2 (ru) 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
RU2539029C2 (ru) 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
MX356279B (es) * 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
CA3185317A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP3033107A1 (en) 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
CN109476733A (zh) * 2016-07-19 2019-03-15 诺华股份有限公司 使用il-17拮抗剂治疗新发斑块型银屑病的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103153A1 (en) * 2014-12-22 2016-06-30 Novartis Ag Pharmaceutical products and stable liquid compositions of il-17 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIAMANT THACI; ANDREW BLAUVELT; KRISTIAN REICH; ET AL: "SECUKINUMAB IS SUPERIOR TO USTEKINUMAB IN CLEARING SKIN OF SUBJECTS WITH MODERATE TO 以下備考", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. VOL:73, NR:3, JPN5019006390, September 2015 (2015-09-01), US, pages 400 - 409, ISSN: 0004545931 *
RICHARD G LANGLEY; BONI E ELEWSKI; MARK LEBWOHL; ET AL: "SECUKINUMAB IN PLAQUE PSORIASIS - RESULTS OF TWO PHASE 3 TRIALS", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:371, NR:4, JPN5019006389, 24 July 2014 (2014-07-24), US, pages 326 - 338, XP055414280, ISSN: 0004716046, DOI: 10.1056/NEJMoa1314258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023064023A (ja) * 2021-10-25 2023-05-10 良丹 孫 乾癬を治療／抑制するための医薬の製造における試薬の使用

Also Published As

Publication number Publication date
ES2992409T3 (es) 2024-12-12
CN109476733A (zh) 2019-03-15
JP2024001125A (ja) 2024-01-09
JP2022126791A (ja) 2022-08-30
EP3487881A1 (en) 2019-05-29
JP2025102888A (ja) 2025-07-08
WO2018015880A1 (en) 2018-01-25
US20190194311A1 (en) 2019-06-27
EP4477265A2 (en) 2024-12-18
EP3487881B1 (en) 2024-08-21
US20230303677A1 (en) 2023-09-28
EP4477265A3 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US20250161443A1 (en) Methods of administering secukinumab
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
US20230303677A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP7341996B2 (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
HK40037862A (en) Methods of treating psoriasis using il-17 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220301